New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

New Study Shows Fresh Grapes Protect the Heart Like Wine

FRESNO, Calif., Nov. 8 /PRNewswire/ -- According to an article just published in the November 2002 Journal of Cardiovascular Pharmacology, eating fresh grapes provides the same heart-health benefits touted for red wine.

A growing body of research suggests that the polyphenols in wine and juice -- polyphenols also found in table grapes -- are largely responsible for the well-publicized health benefits of red wine. In this latest study, researchers at the University of Connecticut tested whether grapes and their component polyphenols are also heart-protective. They found that table grapes from California protected the heart and blood vessels against oxidative tissue damage, similar to the effects of red wine.

Table grapes and wine contain many of the same polyphenols -- disease- fighting phytonutrients such as resveratrol, anthocyanins, catechins, and quercetin. In this new study, researchers confirmed that grape polyphenols are effective antioxidants in two ways. Grape polyphenols scooped up and inactivated free radicals. Grapes also reduced by half the production of malondialdehyde, a by-product of oxidation.

In the same study, researchers tested the protective effect of the polyphenol-rich grapes in a model that mimics what happens during and after a heart attack. Deprivation and re-introduction of blood to the heart and blood vessels can lead to inflammation, blood loss and permanent tissue damage. The damage is due in part to a dramatic rise in free radicals, which overwhelms the heart's normal antioxidant mechanisms that counteract free radical action. California table grape consumption improved blood flow and heart pumping capacity, and reduced the area of tissue death after a heart attack. Researchers attributed these effects mainly to the antioxidant effect of grapes.

"Several investigators now believe fresh grapes and wine are equally cardioprotective," said Dr. Dipak K. Das, principal investigator on the study. "In the past I studied individual grape polyphenols, which are antioxidants and highly cardioprotective, and now have worked with whole grapes, which have the same effects."

For years, researchers have told us that drinking wine is good for the heart. More recently, grape juice was shown to help reduce susceptibility of LDL to oxidation and blood's tendency to form clots. This latest research shows that fresh grapes also provide antioxidant protection.

Cargill Introduces OptaFlex™;The First North American-Source of Solvent-Free Chondroitin Sulfate

New OptaFlex™ is premium quality white, low odor product

MINNEAPOLIS – November 11, 2002 – Cargill Health and Food Technologies (H&FT) announces the breakthrough development of OptaFlex™-- the first solvent-free chondroitin sulfate derived from 100 percent North American sources.
“We are extremely excited to launch this highly unique and valuable product. Through proprietary technology we are able to produce this natural chondroitin sulfate without the use of traditional solvents,” said Ted Ziemann, president of Cargill Health & Food Technologies. Steve Snyder, director sales & marketing, H&FT, said: “OptaFlex™ is an innovative product that will provide a point of differentiation for our customers. We believe dietary supplement manufacturers will recognize the value a North American sourced, solvent-free premium chondroitin sulfate can bring to their products.”
“Chondroitin sulfate/glucosamine has been the number one [selling] specialty supplement for the past five years, according to the Nutrition Business Journal Supplement Business Report 2002,” said Roberta Rosenberg, director of marketing research, H&FT. “OptaFlex™ will complement Cargill’s Regenasure™, a non-shellfish glucosamine product being launched next year.”
Cargill Health & Food Technologies, based in Minneapolis, is a leading developer, processor and marketer of science-based, healthy ingredients for food and dietary supplements worldwide. It is a business unit of Cargill, Incorporated, an international marketer, processor and distributor of agricultural, food, financial and industrial products and services with 97,000 employees in 59 countries. Cargill provides distinctive customer solutions in supply chain management, food applications, and health and nutrition.

###

Twinlab Corporation Announces Executive Retirements; Neil and Brian Blechman Will Leave the Company

HAUPPAUGE, N.Y.--(BUSINESS WIRE)--Nov. 11, 2002--Twinlab Corporation (NASDAQ: TWLB) announced today that after thirty years with the Company Neil Blechman and Brian Blechman have retired as Executive Vice Presidents.
Both will remain available to continue the succession planning that began some time ago to ensure the completion of a smooth transition of their responsibilities. They are continuing to serve on the Twinlab Board of Directors.

Neil Blechman joined Twin Laboratories, Inc. in 1972 with responsibility for marketing and advertising, creative services and consumer affairs. He became an Executive Vice President and Director of the Company in 1996. David Cohen - Vice President of Marketing will assume responsibility for the marketing and creative services functions of the Company.

Neil Blechman added: "I am proud to have played a major role in the development of one of the most trusted brand names in the industry. My thirty years with Twinlab have been extremely gratifying. However, with a strong management team in place, now is the time for me to move on and leverage my strategic and marketing expertise in other areas."

Brian Blechman also joined Twin Laboratories, Inc. in 1972 with responsibility for product formulation, manufacturing, distribution and quality control. He became an Executive Vice President and Director of the Company in 1996. Brian Richmond - Vice President of Operations will assume responsibility for management of the operational functions of the Company.

Brian Blechman continued: "I have seen numerous changes and advancements during my years with Twinlab. I believe that the recent plant consolidation in Utah will provide for a more streamlined operational configuration. The management team that I have worked with and leave in charge is highly qualified to carry on my duties."

Ross Blechman, CEO and President stated: " We wish both Neil and Brian the very best as they move into the next exciting chapters of their lives. The entire Twinlab organization thanks them for their many contributions and years of devoted service to the Company."

Except for historical information contained herein, this release contains, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, forward-looking statements that are based on management's beliefs and assumptions, current expectations, estimates and projections. Many of the factors that will determine the Company's financial results are beyond the ability of the Company to control or predict. These statements are subject to risks and uncertainties and therefore actual results may differ materially. The Company disclaims any obligation to update any forward-looking statements whether as a result of new information, future events, or otherwise. Important factors and risks that may affect future results include but are not limited to: (i) the impact of competitive products; (ii) changes in law and regulations; (iii) adequacy and availability of insurance coverage; (iv) limitations on future financing; (v) increases in the cost of borrowings and unavailability of debt or equity capital; (vi) the effect of adverse publicity regarding nutritional supplements; (vii) uncertainties relating to acquisitions; (viii) the inability of the Company to gain and/or hold market share; (ix) exposure to and expense of resolving and defending product liability claims and other litigation; (x) consumer acceptance of the Company's products; (xi) managing and maintaining growth; (xii) customer demands; (xiii) the inability to integrate and consolidate its manufacturing and distribution facilities and achieve cost savings and operational efficiencies; (xiv) dependence on individual products; (xv) dependence on individual customers, (xvi) market and industry conditions including pricing, demand for products, levels of trade inventories and raw materials availability, (xvii) the success of product development and new product introductions into the marketplace including the Company's line of ephedra-free products; (xviii) lack of available product liability insurance for ephedra-containing products; (xix) slow or negative growth in the nutritional supplement industry; (xx) the departure of key members of management; (xxi) the absence of clinical trials for many of the Company's products; (xxii) the ability of the Company to efficiently manufacture its products; as well as other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, copies of which are available upon request from the Company's investor relations department.

Additional Twinlab information is available on the World Wide Web at: http://www.twinlab.com


Loders Croklaan Lipid Nutrition Announces GRAS Determination of MarinolTM Brand Omega-3 Fatty Acid Products for U.S. Food Market

FDA Confirms GRAS Determination of MarinolTM

CHANNAHON, Ill., November 11, 2002 -- Loders Croklaan Lipid Nutrition, a global leader in lipid-based health ingredients, announced that the FDA confirmed GRAS determination of MarinolTM C-38, an Omega-3 fatty acid product.

The Department of Health and Human Services of the FDA contacted Lipid Nutrition regarding GRAS Notice No. GRN 000105 to inform the company that, based on the information provided by Lipid Nutrition, as well as other information available to the FDA, the agency has no questions at this time regarding Lipid Nutrition¡¦s conclusion that MarinolTM C-38 is GRAS under the intended conditions of use. MarinolTM C-38 is intended for use in wet sauce & wet soup applications, salad dressings and milk. As a major ingredient in the MarinolTM Powder, it also can be utilized in breads, biscuits, and other bakery applications where it can be dry blended with other ingredients.

"This notice is a positive step in the direction toward getting MarinolTM C-38 and MarinolTM Powder approved for their intended use in foods by the FDA,"said David R. Lewis, Business Unit Manager, North America, for Loders Croklaan Lipid Nutrition.

"We expect the U.S. market to adopt these uses plus expand into many new areas such as fruit beverages, dairy drinks, margarine and dairy spreads, cereals, breads, and even ice cream."

MarinolTM brand products contain high and effective concentrations of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), the omega-3 fatty acids that are known to be responsible for providing health benefits such as brain health and cardiovascular promotion.

Loders Croklaan Lipid Nutrition is a global leader in the supply of scientifically sound lipid ingredients from natural origin, which improve and maintain health and well-being. The company offers a variety of branded products, including ClarinolTM CLA, for weight management.

# # #

Galaxy Nutritional Foods Reports 2nd Quarter 2003 Earnings Per Share of $0.06

Reports a 26% Increase in Operating Profits, EBITDA Up 88% Over Prior Quarter

ORLANDO, Fla., Nov. 11 /PRNewswire-FirstCall/ -- Galaxy Nutritional Foods (Amex: GXY), a leading producer of nutritious plant- based dairy alternatives for the retail and foodservice markets, today announced results for its second quarter of fiscal 2003, ended September 30, 2002. The Company reported fully diluted earnings per share of $0.06 compared to a dilutive loss per share of $(0.59) for its second quarter of fiscal 2002, ended September 30, 2001.

For its second quarter ended September 30, 2002, the Company reported net income available to common shareholders, after preferred stock dividends, of $765,133, or $0.06 per-share diluted, compared to a net loss of $(5,893,800), or $(0.59) per-share diluted for the same period one year-ago. Operating income for the second quarter of fiscal 2003 was $1,701,875 versus an operating loss of $(4,327,079) for the second quarter last year. Approximately $1.35 million of the $1.7 million net operating profit was income from non-cash benefit related to stock options and warrants.

Gross margin in the second quarter ended September 30, 2002 was up to 30% as compared with 16% for the second quarter last year. Gross margin has increased to 29% for the first six months of fiscal 2003 from an annual rate of 19% in fiscal 2002. EBITDA less non-cash items for the second quarter ended September 30, 2002 was $1,261,298 or 12.5%. This represents a $590,844 EBITDA increase, or 88%, from the prior quarter ended June 30th, 2002 when EBITDA was $670,454, or 6.7%. EBITDA for the three months ended September 30, 2002 does not include $337,337 expense related to the reserve for doubtful accounts and promotions and the aforementioned $1.35 million non-cash benefit related to stock options and warrants.

Net sales for the quarter were $10,117,995 compared to net sales of $11,372,764 for the comparable quarter one year ago, a decrease of 11%.

Angelo S. Morini, Chairman, President, and Chief Executive Officer of Galaxy, stated, "While we are pleased to have achieved two consecutive quarters of growing operating profitability, sales for the past three consecutive quarters have remained at approximately the same level due primarily to a tactical change of our product mix. This successful strategy has allowed the Company to be profitable at manageable levels. As our operating cash flow improves, we believe we will begin to recognize the benefits of our strategic investment spending on new production equipment. Additionally, we are working on our financial re-structuring, which once completed, should help us grow sales at a faster rate. The demand for our products has never wavered and is stronger than ever. Our market category, one of the fastest growing in the food industry, is expected to grow substantially over the next decade and beyond. I therefore have little doubt that once we have completed our re-financing, we will be on our way to returning to our historical rapid sales growth patterns."

"I believe it is very important at this time to continue strengthening our internal controls and efficiencies, continue to stabilize our raw material costs, and concentrate our selling focus on our higher-margin products," Morini continued. "These measures have positively affected our gross margin, operating profit, cash flow and EBITDA and we expect these controls and strategies will continue to keep Galaxy on a positive operating path."

CONFERENCE CALL INFORMATION

Galaxy will host a teleconference and Webcast to discuss its second quarter 2003 results at 10:00 a.m. EST today, Monday, November 11, 2002. To participate in the conference call, please dial 1-888-208-1812 (United States) or 1-719-457-2654 (International). The call will be simultaneously Webcast at the following link: http://www.firstcallevents.com/service/ajwz369851557gf12.html

For those unable to participate in the live conference, there will be an audio replay available from November 11, 2002 after the call through November 15, 2002 at midnight, by dialing 1-888-203-1112 (Domestic) or 1-719-457-0820 (International) and entering the pass code: 712040 for both telephone numbers. In addition, the call will be posted to Galaxy's website the following week at: http//www.galaxyfoods.com.

ABOUT GALAXY NUTRITIONAL FOODS

Galaxy Nutritional Foods(R) is the leading producer of health-promoting plant-based dairy and dairy-related alternatives for the retail and foodservice markets. An exclusive, new and technologically advanced, safer "hot process" is used to produce these phytonutrient-enriched products, made from nature's best grains -- soy, rice and oats. Veggie products are low fat and fat free (saturated fat and trans-fatty acid free), cholesterol and lactose free, are growth hormone and antibiotic free, and have more calcium, vitamins and other minerals than conventional dairy products. Because they are made with plant proteins, the products are more environmentally friendly and economically efficient than dairy products derived solely from animal proteins. Galaxy's products are part of the healthy and natural foods category, the fastest growing segment of the retail food market. Galaxy brand names include: Galaxy Nutritional Foods(R); Veggie(R); Nature's Alternative(TM); Veggie Lite Bakery(TM); Veggie Cafe(TM); Soyco(R); Soymage(R); Wholesome Valley(R); Lite Bakery(R); and formagg(R). For more information, please visit Galaxy's website at: http://www.galaxyfoods.com.

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward- looking statements involve known and unknown risks, uncertainties, or other factors which may cause actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date hereof. The company undertakes no obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect unanticipated events or developments.

U.S. Nutraceuticals Appoints New Raw Materials Manager

Eustis, FL – Florida based U.S. Nutraceuticals, a leading manufacturer of high quality supercritical-fluid extracts for the dietary supplement, functional food and beverage industries has appointed a new raw materials manager for its Botanics Division. Daniel Vickers will be responsible for purchasing and inventory management of bulk botanicals the company offers through its Botanics Division. Previously Mr. Vickers was the purchasing manager for Gaia Herbs and before that logistics manager for Wilcox Natural Products.

Mr. Vickers will operate out of the U.S. Nutraceuticals LLC office located in Boone, North Carolina. He can be reached at 336-973-8725 or by email at [email protected]. U.S. Nutraceuticals LLC web site: www.usnutra.com

- X X X -

Twinlab Corporation Reports Third Quarter 2002 and Nine Month Results

HAUPPAUGE, N.Y.--(BUSINESS WIRE)--Nov. 11, 2002--Twinlab Corporation (NASDAQ: TWLB) today announced its results for the quarter and nine months ended September 30, 2002.


The Company incurred a net loss of $(26.0) million or $(0.90) per share for the third quarter of 2002, versus a net loss of $(1.8) million or $(0.06) per share for the third quarter of last year. The net loss for the quarter ended September 30, 2002 includes restructuring and asset impairment charges of $6.0 million and $6.9 million, respectively, relating to the previously announced consolidation of the Company's manufacturing and distribution facilities and also includes an incremental charge for sales returns and allowances of $8.8 million recorded in connection with a plan to rationalize product offerings to several key customers. Including this charge, third quarter net sales were $25.2 million compared to $54.0 million in the comparable quarter last year.

For the nine months ended September 30, 2002, the Company incurred a net loss of $(25.9) million or $(0.90) per share, versus a net loss of $(24.7) million or $(0.86) per share for the comparable nine months of 2001. Net sales for the nine months ended September 30, 2002 were $116.1 million compared to $155.7 million in the comparable period last year. The net loss for the nine months ended September 30, 2002 includes restructuring and asset impairment charges totaling $12.9 million and the incremental charge for sales returns and allowances of $8.8 million discussed above, offset by a federal income tax benefit of $6.9 million representing a refund received by the Company. The net loss for the nine months ended September 30, 2001 included the loss on disposal of Changes International of $8.7 million.

The Company also announced today that it has entered into an amendment of its Revolving Credit Facility which, among other things, reduced the total facility from $60.0 million to $50.0 million, revised the financial covenant relating to EBITDA (as defined therein) and increased the commitment fee on the unused portion of the facility by 0.125%.

Ross Blechman, Twinlab's Chairman, President and Chief Executive Officer stated, "Sales and operating results have been negatively impacted by our continued restructuring efforts to enhance future profitability. We have rationalized our product offerings to several key retail customers to achieve a targeted, focused mix resulting in an $8.8 million charge for sales returns and allowances. In July, we announced a comprehensive restructuring plan to reduce costs through the consolidation of our manufacturing and distribution facilities. We now anticipate total charges relating to this consolidation will be approximately $17.0 million, of which $12.9 million was recorded during the current quarter. Although we experienced some disruption in customer service in September and early October, the facilities consolidation is on schedule and proceeding according to plan. Annualized cost reductions associated with the consolidation are still anticipated to be in excess of $6.0 million, beginning in the first quarter of 2003. I am pleased that all of our efforts have been supported by our lenders, as evidenced by the recent amendment to our Revolving Credit Facility which allows for our continued restructuring efforts."

Mr. Blechman added, "As announced earlier today, the Company has decided to discontinue the sale of products that contain ephedra effective March 31, 2003. This decision was reached as a result of increasing costs that are negatively impacting the profitability of these products, coupled with consumer demand for non-epehdra weight loss products. The Company expects to experience a reduction in net sales due to the discontinuation of these products. Based upon anticipated costs savings expected to be achieved, however, the Company does not believe that the decision to discontinue the sale of products that contain ephedra should have a material adverse effect on the profitability of the Company. The Company remains committed to the Diet and Energy category, specifically the Diet Fuel, Ripped Fuel and Metabolift brands, and has launched a line of patented and clinically tested ephedra-free products."

Twinlab Corporation, headquartered in Hauppauge, N.Y., is a leading manufacturer and marketer of high quality, science-based, nutritional supplements, including a complete line of vitamins, minerals, nutraceuticals, herbs and sports nutrition products.

Except for historical information contained herein, this release contains, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, forward- looking statements that are based on management's beliefs and assumptions, current expectations, estimates and projections. Many of the factors that will determine the Company's financial results are beyond the ability of the Company to control or predict. These statements are subject to risks and uncertainties and therefore actual results may differ materially. The Company disclaims any obligation to update any forward-looking statements whether as a result of new information, future events, or otherwise. Important factors and risks that may affect future results include but are not limited to: (i) the impact of competitive products; (ii) changes in law and regulations; (iii) adequacy and availability of insurance coverage; (iv) limitations on future financing; (v) increases in the cost of borrowings and unavailability of debt or equity capital; (vi) the effect of adverse publicity regarding nutritional supplements; (vii) uncertainties relating to acquisitions; (viii) the inability of the Company to gain and/or hold market share; (ix) exposure to and expense of resolving and defending product liability claims and other litigation; (x) consumer acceptance of the Company's products; (xi) managing and maintaining growth; (xii) customer demands; (xiii) the inability to integrate and consolidate its manufacturing and distribution facilities and achieve cost savings and operational efficiencies; (xiv) dependence on individual products; (xv) dependence on individual customers, (xvi) market and industry conditions including pricing, demand for products, levels of trade inventories and raw materials availability, (xvii) the success of product development and new product introductions into the marketplace including the Company's line of ephedra-free products; (xviii) lack of available product liability insurance for ephedra-containing products; (xix) slow or negative growth in the nutritional supplement industry; (xx) the departure of key members of management; (xxi) the absence of clinical trials for many of the Company's products; (xxii) the ability of the Company to efficiently manufacture its products; as well as other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, copies of which are available upon request from the Company's investor relations department.

Additional Twinlab information is available on the World Wide Web at: http://www.twinlab.com

Pilot Therapeutics' Airozin(TM), New OTC Medical Food for Dietary Management Of Asthma, Presented to International Leaders in Allergy and Immunology

WINSTON-SALEM, N.C., Nov. 11 /PRNewswire-FirstCall/ -- Floyd "Ski"
Chilton, Ph.D., president, chief executive officer and chief scientific officer of Pilot Therapeutics Holdings, Inc. (OTC Bulletin Board: PLTT), a specialty pharmaceutical company developing and commercializing a portfolio of pharmaceutical and clinically validated over-the-counter products, presented at the 24th Symposium of the Collegium Internationale Allergeologicum (CIA), held in Bermuda this week.

The Collegium is comprised of the world's most prominent basic and clinical researchers in allergy and immunology. The symposium marks the first introduction of Airozin(TM), Pilot's new medical food product for the dietary management of asthma, to the international medical and research community.

Dr. Chilton's presentation introduced the allergy and immunology community to the "Development of Airozin(TM), A Natural Formulation Clinically Optimized to Inhibit Leukotriene Biosynthesis in Humans." The development of Airozin(TM) was unique in that it applied a systematic approach to developing a safe, efficacious, natural product to regulate key metabolic pathways such as leukotriene biosynthesis. Leukotrienes have been proven to be critical in driving the inflammatory component of asthma.

Dr. Chilton presented the results of four clinical trials that showed that fatty acid content ratios and formulation within Airozin(TM) were optimized to reduce leukotriene synthesis. The conclusion of the studies demonstrated that leukotrienes can be effectively blocked in humans by optimizing the concentrations and formulation of components in a complex natural mixture administered through dietary means.

Dr. Chilton stated that, "Airozin(TM) is now proven to normalize the production of leukotrienes known to cause airway inflammation in people with asthma. This has potential to help asthma sufferers to better manage their condition."

Airozin(TM) provides a new, daily, dietary management alternative for the 20 million Americans with asthma. Additionally, Airozin(TM) fills a previously unmet consumer need for safe and effective over-the-counter asthmamanagement.

About Floyd "Ski" Chilton, Ph.D.
Dr. Chilton is widely recognized for his leading work on the role of arachidonic acid metabolism in human diseases. Prior to joining Pilot Therapeutics as president, chief executive officer and chief scientific officer in December 2000, Dr. Chilton was Director of Molecular Medicine, Professor of Physiology and Pharmacology, Professor of Internal Medicine and Professor of Biochemistry at the Wake Forest University and Johns Hopkins
School of Medicine. Dr. Chilton holds 18 issued and 25 pending patents. He has authored or co-authored over 100 scientific articles and book chapters.

About Pilot
Pilot Therapeutics Holdings, Inc. is a specialty pharmaceutical company that, through its subsidiaries, is developing and commercializing a robust pipeline of pharmaceutical product candidates and clinically validated over-the-counter (OTC) medical food products. A world leader in fatty acid metabolism, Pilot has pioneered Functional Liponomics(TM), a proprietary, state-of-the-art research platform combining fatty acid and genomic profiling,
and has used this research to develop or acquire product candidates for asthma, arthritis, coronary heart disease, cystic acne and cancer. Its lead OTC medical food product, Airozin(TM), is the first clinically proven OTC maintenance product for the dietary management of asthma, a disease that afflicts approximately 20 million Americans. Pilot is in the process of
filing an Investigational New Drug Application (IND) for its lead pharmaceutical product candidate, PLT 732 to treat elevated triglycerides associated with heart disease, diabetes, and stroke. Pilot Therapeutics Holdings, Inc.'s common stock is traded on the Over-the-Counter Bulletin Board under the ticker symbol "PLTT.OB."

Certain statements in this press release are forward-looking in nature and relate to our plans, objectives, estimates and goals. Such statements are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995 and speak only as of the date of this report. The terms "expect," "anticipate," "believe," "intend," "estimate," "plan," and "project" and similar words or expressions are intended to identify forward-looking statements. The forward-looking statements are based on current expectations, are inherently uncertain, are subject to risks, and should be viewed with caution. Our business is subject to many risks and uncertainties, including our ability to register, commercialize or license our products successfully and to promote physician and patient acceptance of our products, our need to obtain substantial additional capital to fund our operations and the progress of development, and the uncertain regulatory environment (and the resulting requirements and restrictions regarding pre-marketing approval and label and promotional claims), surrounding our lead product. These and other risks and uncertainties, many of which are described in more detail in our Annual Report on Form 10-KSB under "Risk Factors," could cause actual results and experience to differ materially from those expressed or implied by any of these forward- looking statements.

For more information about Pilot Therapeutics, visit http://www.pilotp.com .

Garden Burgers Winter Holiday Recipes Add Spice To The Season: Healthy and hearty recipes that won’t leave vegetarians out in the cold

Portland, Ore.—

This winter holiday season, Gardenburger Authentic Foods Company encourages revelers to lose the lentil loaf and serve their vegetarian guests tasty meatless fare that’s as good for them as it is for the planet. Make an impact on the naughty and nice with the meaty taste of Gardenburger Tiki Hut Meatless Meatballs, zesty Original Stuffed Portabella Mushrooms, and lively Thai Chik’n Rollups.

According to a recent study*, nearly one-quarter of Americans consider themselves either full or part-time vegetarians, making it likely that one of your holiday guests will fit that bill. The following festive Gardenburger recipes won’t leave those seeking alternatives out in the cold.

Making the Rounds

Instead of serving up the requisite chips and dips party platter for your vegetarian friends, “wow” them with a plate filled with Gardenburger Tiki Hut Meatless Meatballs. Made with soy protein, breadcrumbs, parmesan cheese, garlic and onions, these ready-made meatballs can be prepared on the stovetop, in the microwave or in the oven. The healthy, bite-sized beauties are available nationwide at food stores and retail for $3.33 per ten ounce box.

Tiki Hut Meatless Meatballs (serves two)

1 box Gardenburger Meatless Meatballs

½ cup favorite sweet and sour sauce

½ cup diced green bell pepper

½ cup diced red bell pepper

¼ cup sliced red onion

½ cup diced fresh pineapple

Sauté peppers, onions and pineapple in a non-stick pan on medium heat until heated through. Cook Meatless Meatballs according to package directions, then add to sauté mixture. Add sweet and sour sauce and heat through. Spoon mixture over rice.

Send ‘em home ‘stuffed’

Twenty minutes until party time? Using Gardenburger Original as a main ingredient in Stuffed Portabella Mushrooms is a real time saver, yet yields elegant results. Now filled with more herbs, spices and real cheddar cheese, the Original can also be served solo alongside a seasonal meal. Gardenburger Original retails for $3.33 per ten ounce box.

Gardenburger Stuffed Portabella Mushrooms (serves four to eight)

8 small portabella mushrooms, cleaned and cap/gills removed

4 Original Gardenburger patties

¼ cup diced roasted red bell pepper

1 T. chopped parsley

3 T. mayonnaise

2 tsp. Dijon mustard

Heat Original patties according to package directions. In a small bowl, gently mash together Gardenburger patties, peppers, parsley, mayo and mustard. Use a tablespoon to scoop stuffing mixture in to the mushrooms. Place under broiler for 5-7 minutes or until heated through. Serve. What a wrapping job!

Okay, so they don’t celebrate Christmas in Thailand. But, if they did, you can bet they would do it by eating Thai Chik'n Rollups featuring Gardenburger’s juicy Chik'n Grill. One bite and your friends will think they’ve died and gone to Asia! Suggested retail price per ten ounce package is $3.50.

Thai Chik'n Rollups (serves four)

4- 8 inch flour tortillas

4 Chik'n Grill Gardenburger patties

Jar of favorite peanut sauce

1 carrot, shredded

8 green onion stalks, julienned

1 cup each shredded red and green cabbage

8 sprigs cilantro

4 sprigs basil

1 tsp. chopped peanuts

Warm tortillas and spread each with one tbsp peanut sauce. Cook Chik’n Grill according to package directions; slice into quarter inch strips. Layer Chik’n Grill strips on tortillas followed by remaining ingredients. Roll up burrito style and serve with additional peanut sauce topped with chopped peanuts.

Additional recipes can be found at www.gardenburger.com. Product samples and digital images are available upon request.

About Gardenburger, official “missionaries of meatless” Founded in 1985, Gardenburger Authentic Foods Company pioneered the original meatless patty, and has been pushing the meatless category to new levels ever since. An independent company, Gardenburger’s vision is to promote pure food and a healthy environment. From the classic, grain-based Gardenburger Original to the groundbreaking barbecue Riblets, the company distributes its meatless products to more than 35,000 foodservice outlets throughout the United States and Canada. Retail customers include more than 30,000 grocery, natural food and club stores. Based in Portland, Ore., the company employs approximately 185 people.

*American Demographics, November 2001.

####

Rexall to be sold by Numico

A Reuters article states that Numico intends to sell Rexall and take a 1.4 billion euro charge, as well as putting GNC on probation.

Numico shares fell following the announcement of lower than expected third quarter numbers, and the company indicated it would focus on higher margin core sectors.

Numico purchased Rexall in 2000 for $1.8 billion, but has been disappointed by the competitive environment, lagging sales and management issues and is now being forced to write down a total of 1.443 billion euros of goodwill, including 1.386 billion euros for US supplement activities alone.

According to Reuters, the company also intends to close its European vitamin business and may consider spinning off Unicity. GNC is being placed under pressure to deliver results and margin in the next 12-18 months.